These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35913764)

  • 1. Immunotherapy with anti-G
    Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
    Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.
    Kushner BH; Modak S; Basu EM; Roberts SS; Kramer K; Cheung NK
    Cancer; 2013 Aug; 119(15):2789-95. PubMed ID: 23633099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
    Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
    Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
    Kushner BH; Kramer K; Modak S; Cheung NK
    J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
    Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
    Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
    Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
    ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
    Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
    Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
    Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
    Wang G; Wang J; Du R; Wang Y; Li Z
    Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
    Slatnick LR; Jimeno A; Gore L; Macy ME
    Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
    Cabral J; Fernandez EI; Toy B; Secola R
    Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.